scispace - formally typeset
K

Ketut Suastika

Researcher at Udayana University

Publications -  88
Citations -  1120

Ketut Suastika is an academic researcher from Udayana University. The author has contributed to research in topics: Population & Diabetes mellitus. The author has an hindex of 14, co-authored 67 publications receiving 669 citations.

Papers
More filters
Journal ArticleDOI

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis.

TL;DR: CCI score should be utilized for risk stratifications of hospitalized COVID-19 patients and is prognostically associated with mortality and associated with a composite of poor outcomes.
Journal ArticleDOI

Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis.

TL;DR: In this paper, the authors performed a systematic literature search from several electronic databases up until 8 September 2020 and reported that increase in CFS was associated with increase in mortality in a linear fashion, and the potential for a nonlinear relationship based on ORs of each quantitative clinical frailty scale was examined using restricted cubic splines with a three-knots model.
Journal ArticleDOI

The DiabCare Asia 2008 study – Outcomes on control and complications of type 2 diabetic patients in Indonesia

TL;DR: Information on diabetes management, diabetes complications, and awareness of self-control in diabetic population of the country, and the physician perspectives, psychological aspects, and quality of life of diabetic patients is collected.
Book ChapterDOI

Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases

TL;DR: Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases.
Journal ArticleDOI

The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis.

TL;DR: Preliminary findings showed that mortality was lowered in those who consume metformin vs who did not, and given its low cost and widespread availability, met formin is an attractive and potential regimen for mitigating excessive risk in diabetic populations.